Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

What next for botulism vaccine development?

Webb RP, Smith LA.

Expert Rev Vaccines. 2013 May;12(5):481-92. doi: 10.1586/erv.13.37. Review.

PMID:
23659297
2.

Botulism and vaccines for its prevention.

Smith LA.

Vaccine. 2009 Nov 5;27 Suppl 4:D33-9. doi: 10.1016/j.vaccine.2009.08.059. Review.

PMID:
19837283
3.

Vaccines against botulism.

Karalewitz AP, Barbieri JT.

Curr Opin Microbiol. 2012 Jun;15(3):317-24. doi: 10.1016/j.mib.2012.05.009. Epub 2012 Jun 12. Review.

PMID:
22694934
4.

Enhancing the protective immune response against botulism.

Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.

Infect Immun. 2013 Jul;81(7):2638-44. doi: 10.1128/IAI.00382-13. Epub 2013 May 13.

5.

Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.

Yu YZ, Liu S, Ma Y, Gong ZW, Wang S, Sun ZW.

Hum Vaccin Immunother. 2014;10(7):1874-9. doi: 10.4161/hv.28937.

6.

Botulinum neurotoxin vaccines: Past history and recent developments.

Rusnak JM, Smith LA.

Hum Vaccin. 2009 Dec;5(12):794-805. Epub 2009 Dec 1. Review.

PMID:
19684478
7.

Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Yu Y, Shi D, Liu S, Gong ZW, Wang S, Sun Z.

Hum Vaccin Immunother. 2015;11(2):468-73. doi: 10.4161/hv.29714.

8.

Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Shone C, Agostini H, Clancy J, Gu M, Yang HH, Chu Y, Johnson V, Taal M, McGlashan J, Brehm J, Tong X.

Infect Immun. 2009 Jul;77(7):2795-801. doi: 10.1128/IAI.01252-08. Epub 2009 Apr 27.

9.

Development of vaccines for prevention of botulism.

Byrne MP, Smith LA.

Biochimie. 2000 Sep-Oct;82(9-10):955-66. Review.

PMID:
11086225
10.

Botulinum neurotoxin vaccines: past, present, and future.

Smith LA, Rusnak JM.

Crit Rev Immunol. 2007;27(4):303-18. Review.

PMID:
18197811
11.

Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.

Moreira C Jr, da Cunha CE, Moreira GM, Mendonça M, Salvarani FM, Moreira ÂN, Conceição FR.

Anaerobe. 2016 Aug;40:58-62. doi: 10.1016/j.anaerobe.2016.05.012. Epub 2016 May 25.

PMID:
27236078
12.

Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA.

Vaccine. 2007 May 22;25(21):4273-82. Epub 2007 Mar 16.

PMID:
17395341
13.

Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Gil LA, da Cunha CE, Moreira GM, Salvarani FM, Assis RA, Lobato FC, Mendonça M, Dellagostin OA, Conceição FR.

PLoS One. 2013 Jul 31;8(7):e69692. doi: 10.1371/journal.pone.0069692. Print 2013.

14.

New targets in the search for preventive and therapeutic agents for botulism.

Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D, Locatelli CA.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1075-86. doi: 10.1586/14787210.2014.945917. Epub 2014 Aug 4. Review.

PMID:
25089560
15.

Oral vaccination with an adenovirus-vectored vaccine protects against botulism.

Chen S, Xu Q, Zeng M.

Vaccine. 2013 Feb 4;31(7):1009-11. doi: 10.1016/j.vaccine.2012.12.054. Epub 2013 Jan 4.

16.

Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.

Gao YL, Gao S, Kang L, Nie C, Wang JL.

Hum Vaccin. 2010 Jun;6(6):462-6. Epub 2010 Jun 1.

PMID:
20519939
17.
18.

Recombinant holotoxoid vaccine against botulism.

Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR.

Infect Immun. 2008 Jan;76(1):437-42. Epub 2007 Oct 29.

19.

Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.

White DM, Pellett S, Jensen MA, Tepp WH, Johnson EA, Arnason BG.

Infect Immun. 2011 Aug;79(8):3388-96. doi: 10.1128/IAI.00166-11. Epub 2011 May 16.

20.

Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B).

Shearer JD, Manetz TS, House RV.

Vaccine. 2012 Mar 2;30(11):1917-26. doi: 10.1016/j.vaccine.2012.01.035. Epub 2012 Jan 23.

PMID:
22269871

Supplemental Content

Support Center